Defining an extended-spectrum β-lactamase

Slides:



Advertisements
Similar presentations
Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages
Advertisements

F.M. MacKenzie, C.A. Miller, I.M. Gould 
C.-S. Lee, J.-H. Lee  Clinical Microbiology and Infection 
Bloodstream infections among carriers of carbapenem-resistant Klebsiella pneumoniae: etiology, incidence and predictors  S. Amit, H. Mishali, T. Kotlovsky,
R. Cantón, A. Novais, A. Valverde, E. Machado, L. Peixe, F. Baquero, T
Defining an extended-spectrum β-lactamase
Gut bacterial microbiota and obesity
Approach to diagnosis of infective endocarditis
Migrant health—a cause for concern?
Evolution of extended-spectrum β-lactamases by mutation
In vitro effects of cefotaxime and ceftriaxone on Salmonella typhi within human monocyte-derived macrophages  B. Ekinci, A.Y. Coban, A. Birinci, B. Durupinar,
C.-S. Lee, J.-H. Lee  Clinical Microbiology and Infection 
J.-P. Van geertruyden  Clinical Microbiology and Infection 
Evaluation of VITEK 2 for analysis of Enterobacteriaceae using the Advanced Expert System (AES) versus interpretive susceptibility guidelines used at.
R. Cantón  Clinical Microbiology and Infection 
Genital Chlamydia trachomatis infections
L. Poirel, P. Nordmann  Clinical Microbiology and Infection 
Louis Pasteur, from crystals of life to vaccination
Extended-spectrum β-lactamase/AmpC- and carbapenemase-producing Enterobacteriaceae in animals: a threat for humans?  J.-Y. Madec, M. Haenni, P. Nordmann,
How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development  R. Bax  Clinical Microbiology.
Impact of changes in CLSI and EUCAST breakpoints for susceptibility in bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia.
How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach  D. Guillemot  Clinical Microbiology.
Vector control: a cornerstone in the malaria elimination campaign
J.P. Donnelly, B.E. De Pauw  Clinical Microbiology and Infection 
Acute renal failure associated with vancomycin and β-lactams for the treatment of osteomyelitis in diabetics: piperacillin–tazobactam as compared with.
New Delhi metallo-beta-lactamase (NDM-1): towards a new pandemia?
C-3′Quaternary Ammonium Cephems, a New Wave of Cephalosporins
Multicenter study of the in vitro activity of cefepime in comparison with five other broad- spectrum antibiotics against clinical isolates of Gram-positive.
Training for the infectious diseases speciality in Norway
Cephalosporins: a pharmacological update
B. Gordts  Clinical Microbiology and Infection 
CMI editorial report 2011 Clinical Microbiology and Infection
Control of infections due to extended-spectrum β-lactamase-producing organisms in hospitals and the community  R.E. Warren, G. Harvey, R. Carr, D. Ward,
C. Varela, A. Oliver, T.M. Coque, F. Baquero, R. Canton 
A comparative study of the in vitro activity of meropenem and representatives of the major classes of broad-spectrum antibiotics  J. Moira Greenhalgh,
Elements of design: the knowledge on which we build
Four-year epidemiological study of extended-spectrum β-lactamase-producing Enterobacteriaceae in a French teaching hospital  L. Gibold, F. Robin, R.-N.
Levofloxacin in the treatment of ventilator-associated pneumonia
R. Bitterman, M. Paul, D. Polak, Y. Geffen 
Metagenomics and probiotics
Laboratory diagnosis of Clostridium difficile disease
The practice of travel medicine in Europe
T.M. File  Clinical Microbiology and Infection 
Long-term study of the frequency of Escherichia coli and Klebsiella pneumoniae isolates producing extended-spectrum β-lactamases  L. Romero, L. López,
Antibacterial drug discovery in the 21st century
Abstracts cont. Clinical Microbiology and Infection
Pandemic lineages of extraintestinal pathogenic Escherichia coli
Jacques Sirot  Clinical Microbiology and Infection 
Current experience in treating invasive zygomycosis with posaconazole
Antimicrobial drug development – the past, the present, and the future
Prevalence and diversity of extended-spectrum ß-lactamases in faecal Escherichia coli isolates from healthy humans in Spain  L. Vinué, Y. Sáenz, S. Martínez,
R. Cantón, A. Novais, A. Valverde, E. Machado, L. Peixe, F. Baquero, T
Statin use and clinical outcomes among pneumonia patients
Clinical Microbiology and Infection
Listeriosis: a resurgent foodborne infection
W. Eugene Sanders, Christine C. Sanders 
K. Kaier, N.T. Mutters, U. Frank  Clinical Microbiology and Infection 
The atypical pneumonias: clinical diagnosis and importance
Predominance of SHV-5 β-lactamase in enteric bacteria causing community-acquired urinary tract infections in Bosnia and Herzegovina  S. Uzunovic-Kamberovic,
Abstracts Clinical Microbiology and Infection
Modelling during an emergency: the 2009 H1N1 influenza pandemic
New oral cephalosporins in pediatric community-acquired infections
B.A. Cunha  Clinical Microbiology and Infection 
J.L. Balcázar  Clinical Microbiology and Infection 
G.C. Schito  Clinical Microbiology and Infection 
G. Kahlmeter  Clinical Microbiology and Infection 
Impact of antibiotic restrictions: the patient's perspective
Comparative study of pediculicidal effect of medical plants
CMI readers' survey Clinical Microbiology and Infection
The future of diagnostic bacteriology
Presentation transcript:

Defining an extended-spectrum β-lactamase D.M. Livermore  Clinical Microbiology and Infection  Volume 14, Pages 3-10 (January 2008) DOI: 10.1111/j.1469-0691.2007.01857.x Copyright © 2008 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 1 Structure of an oxyimino-aminothiazolyl cephalosporin. The C=N–OR group, shaded, is held rigid and shields the β-lactam ring from attack by classic β-lactamases, but not by extended-spectrum β-lactamases. Cefuroxime, cefotaxime, ceftriaxone, ceftazidime, cefepime and cefpirome are all designed on this scaffold. Clinical Microbiology and Infection 2008 14, 3-10DOI: (10.1111/j.1469-0691.2007.01857.x) Copyright © 2008 European Society of Clinical Infectious Diseases Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.